Cerus Corp (CERS) - Product Pipeline Analysis, 2024 Update

Cerus Corp (Cerus) is a biomedical products company that focuses on the field of blood transfusion safety. It develops and commercializes the Intercept blood system, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria, and parasites present in donated blood. The Intercept blood system is for use with blood components including platelets, plasma, and red blood cells. It is also used to produce intercept fibrinogen complex (IFC), and pathogen reduced plasma and cryoprecipitate. The company markets and sells the Intercept blood system through its direct sales force and distributors in several countries including the US, Europe, the Commonwealth of Independent States (CIS), Latin America, the Middle East, and selected countries in other regions. Cerus is headquartered in Concord, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Cerus Corp
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Reasons to Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Cerus Corp Company Overview
Cerus Corp Company Snapshot
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp - Pipeline Analysis Overview
Business Description
Cerus Corp - Key Facts
Cerus Corp - Major Products and Services
Cerus Corp Pipeline Products by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Pipeline Products Overview
INTERCEPT Blood System - Platelets
INTERCEPT Blood System - Platelets Product Overview
INTERCEPT Blood System - Red Blood Cells
INTERCEPT Blood System - Red Blood Cells Product Overview
INTERCEPT Blood System - Red Blood Cells Clinical Trial
INTERCEPT Blood System - Whole Blood
INTERCEPT Blood System - Whole Blood Product Overview
LyoCryo
LyoCryo Product Overview
Next Generation INTERCEPT Blood System
Next Generation INTERCEPT Blood System Product Overview
Cerus Corp - Key Competitors
Cerus Corp - Key Employees
Cerus Corp - Key Employee Biographies
Cerus Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cerus Corp, Recent Developments
Mar 26, 2024: Cerus Announces FDA Approval of Extended Shelf Life for Intercept Platelet Processing Sets - Doubling Previous Shelf Life
Mar 20, 2024: Cerus announces positive results in blood purification trial
Feb 26, 2024: Growing Demand for Cerus’ INTERCEPT Pathogen Inactivation System for Plasma Drives Additional Investment in Microsize’s Particle Sizing Services.
Nov 01, 2023: Bloodbuy Announces Agreement With Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on Its Digital Marketplace
Nov 01, 2023: Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace
Oct 10, 2023: Cerus Announces Workshop and Abstracts at the 2023 AABB Annual Meeting
Sep 27, 2023: Cerus Corp. Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
Jun 05, 2023: Cerus Corporation announces follow-on award of U.S. Department of Defense funding for development of pathogen reduced, Lyophilized Cryoprecipitate
Jan 09, 2023: Cerus Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update
Nov 02, 2022: Cerus announces award of U.S. Department of Defense Funding for development of Pathogen Reduced, Lyophilized Cryoprecipitate
Appendix
Methodology
About the Analyst
Contact the Publisher
Disclaimer

List of Tables

Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp Pipeline Products by Equipment Type
Cerus Corp Pipeline Products by Indication
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp, Key Facts
Cerus Corp, Major Products and Services
Cerus Corp Number of Pipeline Products by Development Stage
Cerus Corp Pipeline Products Summary by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Ongoing Clinical Trials Summary
INTERCEPT Blood System - Platelets - Product Status
INTERCEPT Blood System - Platelets - Product Description
INTERCEPT Blood System - Red Blood Cells - Product Status
INTERCEPT Blood System - Red Blood Cells - Product Description
INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures
INTERCEPT Blood System - Red Blood Cells - Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections and Treatment Use Open-label Extension Study
INTERCEPT Blood System - Whole Blood - Product Status
INTERCEPT Blood System - Whole Blood - Product Description
LyoCryo - Product Status
LyoCryo - Product Description
Next Generation INTERCEPT Blood System - Product Status
Next Generation INTERCEPT Blood System - Product Description
Cerus Corp, Key Employees
Cerus Corp, Key Employee Biographies
Cerus Corp, Subsidiaries
Glossary

List of Figures

Cerus Corp Pipeline Products by Equipment Type
Cerus Corp Pipeline Products by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Octapharma AG
MacoPharma International Gmbh
Kedrion Biopharma Inc
Terumo BCT Inc
Grifols SA